(NASDAQ: LEXX) Lexaria Bioscience's forecast annual revenue growth rate of 109.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.55%.
Lexaria Bioscience's revenue in 2026 is $194,000.On average, 4 Wall Street analysts forecast LEXX's revenue for 2026 to be $353,965, with the lowest LEXX revenue forecast at $32,389, and the highest LEXX revenue forecast at $694,048. On average, 3 Wall Street analysts forecast LEXX's revenue for 2027 to be $2,364,722, with the lowest LEXX revenue forecast at $2,272,182, and the highest LEXX revenue forecast at $2,434,127.
In 2028, LEXX is forecast to generate $2,672,086 in revenue, with the lowest revenue forecast at $2,566,326 and the highest revenue forecast at $2,749,753.